Jinrui recently attended the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, where members of the company's team met with biotechnology and pharmaceutical industry representatives from North America, Europe, and Asia.

The discussions focused on emerging developments in neuro-oncology, ongoing challenges in the treatment of glioblastoma, and potential opportunities for scientific and business collaboration. During these exchanges, Jinrui introduced its development programs and shared updates on JRF101, the company's investigational therapy for recurrent glioblastoma (GBM).

JRF101 has demonstrated encouraging clinical activity in patients with recurrent or progressive GBM. In the study, 3-, 6-, and 9-month survival rates reached 85.0%, 53.8%, and 39.3%, respectively, exceeding those observed in the control group. Among patients who completed the planned treatment course, the 9-month survival rate increased to 52.7%. The therapy also demonstrated a favorable safety profile, with a lower incidence of Grade 3 or higher adverse events than the control arm and no severe myelosuppression observed.

Recurrent glioblastoma remains one of the most difficult-to-treat cancers, with limited therapeutic options and poor clinical outcomes. Jinrui believes that continued scientific innovation and international collaboration will be important to advancing new treatment approaches for patients with this disease.

The company is currently focused on completing its ongoing Phase II clinical study in China and generating a comprehensive clinical data package. Jinrui is also exploring opportunities to support the future global development of JRF101. The program has received FDA clearance for clinical investigation in the United States and has been granted Orphan Drug Designation.

By engaging with stakeholders across the global biotechnology ecosystem, Jinrui aims to build relationships that can support the continued development of innovative therapies for patients with high unmet medical needs.